In Memoriam

Richard Whittington, M.D.

faculty photo
Department: Radiation Oncology

Contact information
Philadelphia Veterans Medical Center
Department of Radiation Oncology
Philadelphia, PA 19104
BA (Biology and History)
Rice University , 1972.
Thomas Jefferson University, 1976.
Permanent link
> Perelman School of Medicine   > Faculty   > Details

Selected Publications

D'Amico AV. Chen MH. Malkowicz SB. Whittington R. Renshaw AA. Tomaszewski JE. Samofalov Y. Wein A. Richie JP: Lower prostate specific antigen outcome than expected following radical prostatectomy in patients with high grade prostate and a prostatic specific antigen level of 4 ng/ml.or less. Journal of Urology 167(5): 2025-30, 2002.

D'Amico, A.V., Whittington, R., Malkowicz, S.B., Blank, K., Broderick, G.A., Schultz, D., Tomaszewski, J.E., Wein, A.J. : A prostate specific antigen outcome after permanent interstitial radiation therapy in low risk prostate cancer patients with T2a vs. T1c disease. Int J Rad Oncol Biol Phys 2003.

Jones HA. Metz JM. Devine P. Hahn SM. Whittington R. : Rates of unconventional medical therapy use in patients with prostate cancer: standard history versus directed questions. Urology 59(2): 272-6, 2002.

Lieberfarb ME. Schultz D. Whittington R. Malkowicz B. Tomaszewski JE. Weinstein M. Wein A. Richie JP. D'Amico AV. : Using PSA, biopsy Gleason score, clinical stage, and the percentage of positive biopsies to identify optimal candidates for prostate-only radiation therapy. International Journal of Radiation Oncology, Biology, Physics. 53(4): 898-903, 2002.

D'Amico AV. Whittington R. Malkowicz SB. Cote K. Loffredo M. Schultz D. Chen MH. Tomaszewski JE. Renshaw AA. Wein A. Richie JP. : Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era. Cancer. 95(2): 281-6, 2002.

Robnett TJ. Whittington R. Malkowicz SB. Brereton HD. Van Arsdalen K. Drach G. Wein AJ.: Long-term use of combined radiation therapy and hormonal therapy in the management of stage D1 prostate cancer. International Journal of Radiation Oncology, Biology, Physics. 53(5): 1146-51, 2002.

Cross CK. Shultz D. Malkowicz SB. Huang WC. Whittington R. Tomaszewski JE. Renshaw AA. Richie JP. D'Amico AV: Impact of race on prostate-specific antigen outcome after radical prostatectomy for clinically localized adenocarcinoma of the prostate. Journal of Clinical Oncology 20(12): 2863-8, 2002.

Whittington, R., Bloch, P., Hutchinson, D., Bjarngard, B. : Verification of prostate treatment setup using computed radiography for portal imaging. J Appl Clin Med Phys 3: 88-96, 2002.

D'Amico AV. Whittington R. Malkowicz SB. Weinstein M. Tomaszewski JE. Schultz D. Rhude M. Rocha S. Wein A. Richie JP: Predicting prostate specific antigen outcome preoperatively in the prostate specific antigen era. Journal of Urology 166(6): 2185-8, 2001.

Cheung R. Altschuler MD. D'Amico AV. Malkowicz SB. Wein AJ. : ROC optimization may improve risk stratification of prostate cancer patients. Urology. 57(2): 286-90, 2001.

back to top
Last updated: 12/27/2006
The Trustees of the University of Pennsylvania